Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Quest Diagnostics Incorporated is a diagnostics & research business based in the US. Quest Diagnostics Incorporated shares (DGX) are listed on the NYSE and all prices are listed in US Dollars. Quest Diagnostics Incorporated employs 50,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$153.52|
|52-week range||$106.26 - $160.56|
|50-day moving average||$150.89|
|200-day moving average||$135.33|
|Wall St. target price||$157.67|
|Dividend yield||$2.36 (1.52%)|
|Earnings per share (TTM)||$16.71|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||-0.81%|
|1 month (2021-08-24)||2.67%|
|3 months (2021-06-24)||18.83%|
|6 months (2021-03-24)||20.99%|
|1 year (2020-09-24)||40.60%|
|2 years (2019-09-24)||44.27%|
|3 years (2018-09-24)||42.69%|
|5 years (2016-09-23)||79.68%|
Valuing Quest Diagnostics Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Quest Diagnostics Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Quest Diagnostics Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Quest Diagnostics Incorporated shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Quest Diagnostics Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2271. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Quest Diagnostics Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Quest Diagnostics Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.3 billion.
The EBITDA is a measure of a Quest Diagnostics Incorporated's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$11.1 billion|
|Operating margin TTM||25.98%|
|Gross profit TTM||$3.7 billion|
|Return on assets TTM||13.89%|
|Return on equity TTM||39.08%|
|Market capitalisation||$18.9 billion|
TTM: trailing 12 months
There are currently 5.9 million Quest Diagnostics Incorporated shares held short by investors – that's known as Quest Diagnostics Incorporated's "short interest". This figure is 17.5% down from 7.2 million last month.
There are a few different ways that this level of interest in shorting Quest Diagnostics Incorporated shares can be evaluated.
Quest Diagnostics Incorporated's "short interest ratio" (SIR) is the quantity of Quest Diagnostics Incorporated shares currently shorted divided by the average quantity of Quest Diagnostics Incorporated shares traded daily (recently around 1.1 million). Quest Diagnostics Incorporated's SIR currently stands at 5.56. In other words for every 100,000 Quest Diagnostics Incorporated shares traded daily on the market, roughly 5560 shares are currently held short.
However Quest Diagnostics Incorporated's short interest can also be evaluated against the total number of Quest Diagnostics Incorporated shares, or, against the total number of tradable Quest Diagnostics Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Quest Diagnostics Incorporated's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Quest Diagnostics Incorporated shares in existence, roughly 50 shares are currently held short) or 0.0489% of the tradable shares (for every 100,000 tradable Quest Diagnostics Incorporated shares, roughly 49 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Quest Diagnostics Incorporated.
Find out more about how you can short Quest Diagnostics Incorporated stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Quest Diagnostics Incorporated.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 18.33
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Quest Diagnostics Incorporated's overall score of 18.33 (as at 12/31/2018) is excellent – landing it in it in the 16th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Quest Diagnostics Incorporated is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.86/100
Quest Diagnostics Incorporated's environmental score of 0.86 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Quest Diagnostics Incorporated is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 10.42/100
Quest Diagnostics Incorporated's social score of 10.42 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Quest Diagnostics Incorporated is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.77/100
Quest Diagnostics Incorporated's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Quest Diagnostics Incorporated is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Quest Diagnostics Incorporated scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Quest Diagnostics Incorporated hasn't always managed to keep its nose clean.
|Total ESG score||18.33|
|Total ESG percentile||16.26|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
|Level of controversy||3|
Dividend payout ratio: 15.38% of net profits
Recently Quest Diagnostics Incorporated has paid out, on average, around 15.38% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.6% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Quest Diagnostics Incorporated shareholders could enjoy a 1.6% return on their shares, in the form of dividend payments. In Quest Diagnostics Incorporated's case, that would currently equate to about $2.36 per share.
While Quest Diagnostics Incorporated's payout ratio might seem low, this can signify that Quest Diagnostics Incorporated is investing more in its future growth.
Quest Diagnostics Incorporated's most recent dividend payout was on 19 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 3 October 2021 (the "ex-dividend date").
Quest Diagnostics Incorporated's shares were split on a 2:1 basis on 20 June 2005. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Quest Diagnostics Incorporated shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Quest Diagnostics Incorporated shares which in turn could have impacted Quest Diagnostics Incorporated's share price.
Over the last 12 months, Quest Diagnostics Incorporated's shares have ranged in value from as little as $106.255 up to $160.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Quest Diagnostics Incorporated's is 1.0338. This would suggest that Quest Diagnostics Incorporated's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey. .
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.